General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Research and development

Focus on the patient, follow the science

We create innovative medicines and prioritize our work based on unmet medical need and strong scientific understanding of disease - not the size of the potential commercial market.

Novartis researchers are working to map complex protein signaling networks known as molecular signaling pathways inside of cells. These molecular pathways are highly controlled and interconnected signal-relay systems, similar to communication networks, and are responsible for normal cell function. When a protein in a pathway does not function properly, the result can be abnormal signaling and disease. Scientists at the Novartis Institutes for BioMedical Research (NIBR) develop small molecule drugs or antibodies to target key nodes within pathways that, when defective, lead to disease.

To translate scientific discoveries from the lab bench to the clinic, Novartis uses proof-of-concept clinical trials (small scale studies used to get an early read on a drug’s safety and effectiveness) to help find and advance the most promising drug candidates. These proof-of-concept studies often focus on treating a rare, but genetically well-defined disease.

“We choose to work where there is unmet need and where the science is strongest.”

Mark C. Fishman, M.D., President of NIBR and member of the Executive Committee of Novartis.

By focusing on the patient and following the science, Novartis has discovered innovative treatments for disorders ranging from cancer to degenerative disease

Thanks to this approach, Novartis has one of the strongest and most productive pipelines in the industry, with 141 projects in clinical development, many of which are new molecular entities.

One of the innovative techniques that Novartis researchers use to help find and advance the most promising drug candidates is computer modeling and simulation. Watch the video below to learn about Computer-Aided Drug Design.